Oculis Holding AG
OCS · XICE · Health Care · Ophthalmology · US listing: OCS
About the company
Oculis is a clinical-stage biopharmaceutical company focused on developing treatments for serious eye diseases. It is incorporated in Switzerland and listed on Nasdaq Iceland as well as Nasdaq US. The company's pipeline targets conditions including wet age-related macular degeneration and diabetic macular edema.
| Exchange | XICE |
| Ticker | OCS |
| Sector | Health Care · Ophthalmology |
| US listing | OCS |
| Indicative market cap USD | $465.00M |
| Website | Visit website |
Live quote
Loading live price…
| Market cap | |
| Day range | |
| 52-week range |
Where to buy
Trades in the US as OCS, available through most US brokerage accounts.
On its home market (XICE), it is accessible through global brokers that offer that exchange:
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Nasdaq Iceland, the sole stock exchange in Iceland, is operated by Nasdaq Nordic and uses the trading code XICE. — official exchange listing
Availability information only. Not a recommendation or an offer to buy. Confirm eligibility, fees and current availability with your broker.
Other companies in Iceland
Company data and any live price are indicative, may be delayed or inaccurate, and are for research only. Not investment advice. Verify with the exchange, the company's filings and your broker.